Navigation Links
Aisling Capital Announces Close of US$650M Life Sciences Fund
Date:1/7/2009

NEW YORK, Jan. 7 /PRNewswire/ -- Aisling Capital announced today that it raised US$650 million in committed capital for its newest life sciences fund, Aisling Capital III, LP. Aisling Capital will invest its third fund primarily in companies developing pharmaceutical, biopharmaceutical and medical products, as well as in businesses that provide drug development, manufacturing and other important services to the healthcare industry. With a total of over US$1.6 billion in committed capital under management, the Aisling Capital team will also continue to manage the Perseus-Soros BioPharmaceutical Fund, LP and Aisling Capital II, LP.

"We appreciate the support of our existing and new limited partners, particularly during these times of market turbulence," commented Dennis Purcell, Senior Managing Partner of Aisling Capital. Mr. Purcell added: "We believe the next several years will be a critical period for the life sciences industry, in which multiple forces will converge to create opportunities for the prepared investor."

The Aisling Capital team is comprised of individuals with a combination of clinical, transactional, operational and capital markets expertise, complemented by extensive networks in the life sciences industry. The team is led by Managing Partners Dennis Purcell, Steve Elms and Andrew Schiff, M.D. and newly promoted Partners Dov Goldstein, M.D., Anthony Sun, M.D. and Brett Zbar, M.D. Additionally, Josh Bilenker, M.D. has been promoted to Principal.

About Aisling Capital

Aisling Capital is a dedicated life sciences private equity firm with over US$1.6 billion under management. Headquartered in New York, Aisling Capital invests in both private and public companies utilizing a wide variety of investment structures. The Aisling Capital team's combination of clinical, operational and financial experience allows the firm to identify, execute and realize investments across the life
'/>"/>

SOURCE Aisling Capital
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
2. Rigel to Participate at the RBC Capital Markets Healthcare Conference
3. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
4. Micromet to Present at the RBC Capital Markets Healthcare Conference
5. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
6. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
7. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
8. Abaxis, Inc. to Present at the RBC Capital Markets 2008 Healthcare Conference
9. Medarex to Present at the RBC Capital Markets Healthcare Conference
10. Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference
11. Jazz Pharmaceuticals Cancels Presentation Planned for November 19, 2008 at Lazard Capital Markets 5th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... in Australia through ... retail pharmacies nationwide, TAMPA, Fla., ... leader in pharmacy-based patient care services and,healthlinks.net, a subsidiary of ... a definitive technology licensing and business,consulting agreement, paving the way ...
... to receive funding for preclinical and clinical research projects ... ... ROCKLAND, Mass., Oct. 14 The Michael J. Fox Foundation,for ... five,research teams to speed development of effective therapies for the,under-addressed ...
... Logix, a privately held,biopharmaceutical company focused on using ... drugs, is pleased to announce the,appointment of Keith ... Chief,Executive Officer and to its Board of Directors. ... years of leadership experience in the,biotechnology industry., ...
Cached Biology Technology:Mirixa Announces Agreement With the Pharmacy Guild of Australia 2Mirixa Announces Agreement With the Pharmacy Guild of Australia 3Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 2Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 3Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 4Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 5Surface Logix Appoints Keith Dionne as President and Chief Executive Officer 2
(Date:4/16/2014)... A 20-year assessment of Nicaragua,s legal, artisanal green sea ... overall catch rates of turtles in what may have ... the Wildlife Conservation Society and University of Florida. , ... than 170,000 green turtles were killed between 1991 and ...
(Date:4/16/2014)... From far away, the top of a leaf looks ... exterior is actually made up of a patchwork of ... in how these cells individually take on their own ... Sampathkumar, and colleagues sought to pinpoint the shape-controlling factors ...
(Date:4/16/2014)... as Kennedy,s disease, spinal and bulbar muscular atrophy (SBMA) is ... weakness and atrophy. Researchers have long considered it to be ... in the spinal cord and brainstem that control muscle movement. ... 16, 2014 online issue of Neuron , a team ...
Breaking Biology News(10 mins):Declining catch rates in Caribbean green turtle fishery may be result of overfishing 2Declining catch rates in Caribbean green turtle fishery may be result of overfishing 3For cells, internal stress leads to unique shapes 2Mutant protein in muscle linked to neuromuscular disorder 2
... heart disease, neurological disorders and other degenerative conditions, some scientists ... are finding you,re not a creature of either genetics or ... approach to health. The new field of "epigenetics" is ... a certain genetic code at conception. But, the choice of ...
... A team of scientists working at beamline 9.0.1 of ... of Energy,s Lawrence Berkeley National Laboratory has used x-ray ... achieving the highest resolution11 to 13 nanometers (billionths of ... Their success indicates that full 3-D tomography of whole ...
... team is studying whether running the Yuma Desalting Plant will ... the Colorado River Delta. The cienega, a 15,000-acre wetland, ... stopover for birds migrating north and south along the Pacific ... to begin its latest trial run May 3. "The ...
Cached Biology News:'Epigenetic' concepts offer new approach to degenerative disease 2'Epigenetic' concepts offer new approach to degenerative disease 3Lensless imaging of whole biological cells with soft X-rays 2Lensless imaging of whole biological cells with soft X-rays 3Lensless imaging of whole biological cells with soft X-rays 4Researchers study effect of yuma desalting plant on Cienega de Santa Clara 2Researchers study effect of yuma desalting plant on Cienega de Santa Clara 3
Rabbit polyclonal to TAB1 ( Abpromise for all tested applications). entrezGeneID: 10454 SwissProtID: Q15750...
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
Rabbit polyclonal to FANCG ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSRQTTSVGSSC, corresponding to amino acids 1 - 12 of Human FANCG. Entrez GeneID: 2189 Swis...
Rabbit polyclonal to ZNF261 ( Abpromise for all tested applications). entrezGeneID: 9203 SwissProtID: Q14202...
Biology Products: